Navigation Links
Genaera Corporation Announces Third Quarter Financial Results
Date:11/9/2007

tements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding the preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with
'/>"/>
SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
6. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015 ... for Open Innovation in Science", som finner ... Søknadene sendes på nett, på  http://www.openinnovationinscience.at , ... 2015.  De to største utfordringene ... å undersøke nye forskningsspørsmål og kompleksiteten av ...
(Date:7/2/2015)... , July 2, 2015  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today announced a ... Spherix Incorporated v. Verizon Services Corp. et al. , ... for the Eastern District of Virginia ... 1, 2015 interpreting certain key claims in favor of ...
(Date:7/1/2015)... PARK, N.C. and PARIS ... research firm AgBiome, and Genective, key developer of ... accelerate the discovery of new generations of insect ... for insect control to counter the realities of ... with Genective, aligning AgBiome,s unique insect control technology ...
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
Breaking Biology Technology:Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... form of Coenzyme Q10 positively impacted heart function ... from the first clinical trial evaluating ubiquinol,s effects ... newly available pre-converted form of Coenzyme Q10 (CoQ10) ... Published in the January 2009 issue of ...
... Plant to Be Commissioned in Coming WeeksLAKE MARY, ... Holdings, Inc. (Nasdaq: NGBF ) ("New ... renewable fuels provider, today announced that construction of ... has reached substantial completion, and operations are expected ...
... Opsona Therapeutics, a,biotechnology company focused on novel therapeutic ... announced the,completion of an EUR18M ($23M) Series B ... at an operational and clinical level. Novartis Venture ... Kernel,Life Sciences all participated in the funding. , ...
Cached Biology Technology:KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure 2KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure 3New Generation Biofuels Completes Construction of Baltimore Facility 2New Generation Biofuels Completes Construction of Baltimore Facility 3Opsona Therapeutics Closes EUR18M Funding 2Opsona Therapeutics Closes EUR18M Funding 3Opsona Therapeutics Closes EUR18M Funding 4
(Date:6/18/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market announces that its Wocket® smart wallet ... on the Mark", scheduled to air on WABC Radio (am770) ... th . The broadcast air- time for ... 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira will ...
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/15/2015)... A new report [ 1 ] ... consumers using mobile banking applications want their mobile devices to ... instead of having to prove who they are with passwords ...   -   The Fusion of Financial Services, Mobile and ... channel used by Gen X and Gen Y to access ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... beneficial effects on a range of human systems, from enhancing ... But it does not improve cholesterol levels, according to a ... of scientists has shown that, at least in the short ... D deficiency received mega-doses of vitamin D. The finding is ...
... Liviu Giosan first reconstructed the history of how the Danube ... In the delta,s early stages of development, the river ... expanded onto the Black Sea shelf in the late Holocene ... seeing the decline in sediment storage that he expected, Giosan ...
... Grant goes to the University of Veterinary Medicine, Vienna ... at the Vetmeduni Vienna has been allocated one of ... (ERC). The award comes with approximately 1.3 million ... the coming five years to investigate the behavioural mechanisms ...
Cached Biology News:Vitamin D supplements do not improve cholesterol as previous research suggested 2Human impact felt on Black Sea long before industrial era 2Human impact felt on Black Sea long before industrial era 3Human impact felt on Black Sea long before industrial era 4ERC starting grant for Friederike Range 2
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Macrophage-stimulating protein receptor...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Biology Products: